(0.06%) 5 157.75 points
(0.08%) 38 863 points
(-0.04%) 17 994 points
(0.47%) $78.48
(0.47%) $2.15
(0.52%) $2 320.50
(1.80%) $27.17
(-0.23%) $963.10
(0.05%) $0.929
(-0.03%) $10.87
(0.04%) $0.797
(0.41%) $91.83
1.12% $ 2.71
@ $2.78
Wydano: 13 vas. 2024 @ 16:30
Zwrot: -2.45%
Poprzedni sygnał: vas. 12 - 16:32
Poprzedni sygnał:
Zwrot: -2.53 %
Live Chart Being Loaded With Signals
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 683 613 |
Średni wolumen | 1.41M |
Kapitalizacja rynkowa | 511.42M |
EPS | $-0.120 ( 2024-05-02 ) |
Następna data zysków | ( $-0.110 ) 2024-05-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.16 |
ATR14 | $0.00400 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Naftzger J. Christopher | Buy | 380 500 | Stock Option (Right to Buy) |
2024-02-01 | Naftzger J. Christopher | Buy | 95 100 | Common Shares |
2024-02-01 | Sims Karen | Buy | 403 900 | Stock Option (Right to Buy) |
2024-02-01 | Sims Karen | Buy | 101 000 | Common Shares |
2024-02-02 | Sims Karen | Sell | 4 358 | Common Shares |
INSIDER POWER |
---|
90.40 |
Last 95 transactions |
Buy: 35 682 262 | Sell: 1 766 657 |
Wolumen Korelacja
Arbutus Biopharma Corp Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
GETVV | 0.964 |
PPBT | 0.935 |
SISI | 0.934 |
DRTT | 0.929 |
WATT | 0.926 |
TPST | 0.925 |
GMBL | 0.925 |
GLMD | 0.921 |
NCBS | 0.921 |
CRTD | 0.918 |
10 Najbardziej negatywne korelacje | |
---|---|
PPSI | -0.942 |
SLAM | -0.941 |
GSHD | -0.937 |
GFGD | -0.937 |
GASS | -0.933 |
AAPL | -0.933 |
UFPI | -0.931 |
NECB | -0.931 |
VERA | -0.93 |
UFPT | -0.93 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Arbutus Biopharma Corp Korelacja - Waluta/Towar
Arbutus Biopharma Corp Finanse
Annual | 2023 |
Przychody: | $18.14M |
Zysk brutto: | $16.74M (92.26 %) |
EPS: | $-0.440 |
FY | 2023 |
Przychody: | $18.14M |
Zysk brutto: | $16.74M (92.26 %) |
EPS: | $-0.440 |
FY | 2022 |
Przychody: | $39.02M |
Zysk brutto: | $37.59M (96.34 %) |
EPS: | $-0.460 |
FY | 2021 |
Przychody: | $10.99M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.830 |
Financial Reports:
No articles found.
Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej